:: ::
Back to the articles list Back to browse issues page
Combination of Chitosan and Myxovirus Resistance Oligonucleotide: An Efficient and Safe Natural Adjuvant against Influenza Virus
Maryam Ahmadi , Gholamreza Hashemi Tabar * , Shahla Shahsavandi
Department of Pathobiology, Faculty of Veterinary Medicine, Ferdowsi University of Mashhad, Mashhad, Iran
Abstract:   (141 Views)
Introduction: Avian influenza virus causes severe economic losses to the poultry industry and has a great potential for becoming a pandemic threat for humans. The application of natural adjuvants has opened up new avenues toward reaching a highly efficient and safe vaccine in recent years.  In this study, we investigated the adjuvant activity of interferon-induced myxovirus resistance (Mx) protein on chitosan-based H9N2 nanoparticles in a BALB/c mouse model. Methods: The inactivated H9N2 virus antigen was encapsulated in chitosan nanoparticles (NPs) using gelation method. Female BALB/c mice were randomly divided into four groups (n=10). Group A received the H9N2-loaded chitosan NPs mixing with Mx intranasally and was boosted twice with a 1-week interval. Group B received the H9N2-loaded chitosan NPs in the same manner. Mice in groups C and D received the chitosan NPs and PBS, respectively as negative controls. Body weights of the mice were measured at defined times. Blood samples were collected from the animals and their influenza-specific antibody titer was determined using ELISA. Results: The results demonstrated a higher antibody level in treated groups A and B as compared to the control samples. We also showed that the combination of Mx and chitosan could significantly induce an influenza-specific antibody titer, indicating synergistic effects of the applied adjuvant and NPs together. Conclusion: The formulation of H9N2 with Mx as an adjuvant and chitosan as a nanocarrier is a promising procedure for developing an efficient vaccine against avian influenza virus.
Keywords: Avian influenza, Chitosan, Mx, Nanoparticles, Immune responses
Full-Text [PDF 996 kb]   (45 Downloads)    
Type of Study: Original article | Subject: Vaccine vectors, adjuvantsand immunomodulators
Received: 2020/10/7 | Accepted: 2020/12/1


XML     Print



Back to the articles list Back to browse issues page